Palatin Technologies, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 34
- Market Cap
- $28.8M
- Website
- http://www.palatin.com
Clinical Trials
13
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (12 trials with phase data)• Click on a phase to view related trials
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide with Tirzepatide for the Treatment of Obesity
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Palatin Technologies, Inc
- Target Recruit Count
- 108
- Registration Number
- NCT06565611
- Locations
- 🇺🇸
University Clinical Research-DeLand LLC, d/b/a Accel Research, DeLand, Florida, United States
🇺🇸Lynn Health Science Institute, Oklahoma City, Oklahoma, United States
🇺🇸Coastal Carolina Research Center, North Charleston, South Carolina, United States
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney Disease
- Conditions
- Kidney Disease
- Interventions
- Drug: RAAS inhibition therapy
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Palatin Technologies, Inc
- Target Recruit Count
- 16
- Registration Number
- NCT05709444
- Locations
- 🇺🇸
Northeast Research Center, LLC, Bethlehem, Pennsylvania, United States
🇺🇸Nephrotex Research Group, Dallas, Texas, United States
🇺🇸California Institute of Renal Research, Chula Vista, California, United States
Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC)
- Conditions
- Ulcerative ColitisUlcerative Colitis AcuteUlcerativeUlcerative Colitis Flare
- Interventions
- Drug: PL8177 Placebo
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Palatin Technologies, Inc
- Target Recruit Count
- 16
- Registration Number
- NCT05466890
- Locations
- 🇺🇸
Del Sol Research Management, LLC, Tucson, Arizona, United States
🇺🇸Gastro Care Institute, Lancaster, California, United States
🇺🇸Valiance Clinical Research, Tarzana, California, United States
A Phase 3, Multi-Center Study Evaluating PL9643 in Patients with Dry Eye
- Conditions
- Dry EyeDry Eye Syndromes
- Interventions
- Drug: PL9643 Ophthalmic SolutionDrug: Vehicle Ophthalmic Solution
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Palatin Technologies, Inc
- Target Recruit Count
- 575
- Registration Number
- NCT05201170
- Locations
- 🇺🇸
Global Research Management, Glendale, California, United States
🇺🇸Eye Research Foundation, Newport Beach, California, United States
🇺🇸East West Eye Institute, Torrance, California, United States
Study to Evaluate Sex Differences in the Acute Effects of PL-3994 in Heart Failure Subjects
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- First Posted Date
- 2020-03-23
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Palatin Technologies, Inc
- Target Recruit Count
- 55
- Registration Number
- NCT04318145
- Locations
- 🇺🇸
Northwestern University, Evanston, Illinois, United States
- Prev
- 1
- 2
- 3
- Next